Xeris Biopharma reports Q3 EPS (11c), consensus (9c)

Reports Q3 revenue $54.27M, consensus $51.43M. “We are proud to report our record-breaking quarter with total revenue of our $54 million led by strong demand of Recorlev(R) and Gvoke(R). Our product revenue growth of 27% marks the 12th consecutive quarter of over 20% growth,” said John Shannon, CEO of Xeris. “We have made investments in areas that drive growth, notably Recorlev(R), and we are seeing the benefits of those investments. Given our exceptional year-to-date performance, we are raising our revenue guidance to $198-$202 million from the previous $190-$200 million. Looking ahead, our focus remains on continuing to drive greater than 20% product revenue growth and advancing our robust pipeline – namely our Phase 3 ready, XP-8121.”